Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

Overview

Información sobre este estudio

The purpose of the study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis to repair an  aneurysm located in the abdominal aorta. Performance of the GORE® EXCLUDER® Conformable AAA Endoprosthesis will be judged by separate performance goals.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Abdominal Aortic Aneurism meeting any of the following criteria:
    • Maximum diameter ≥ 50 mm;
    • Rapid growth > 5 mm in a 6 month period;
    • Non-ruptured AAA presenting with clinical symptoms.
  • Adequate anatomy to receive the GORE® EXCLUDER® Conformable AAA Endoprosthesis, including:
    • Adequate iliac / femoral access;
    • Infrarenal aortic neck diameter 16-32 mm;
    • Infrarenal aortic neck length ≥ 10 mm;
    • Aortic neck angle ≤ 90˚;
    • Distal iliac artery seal zone ≥ 10 mm;
    • Iliac artery diameter 8-25 mm.
  • An Informed Consent Form (ICF) signed by subject.
  • Male or infertile female.
  • Able to comply with protocol requirements including following-up.
  • Life expectancy > 2 years.
  • Age ≥ 21 years.

Exclusion Criteria

  • Mycotic or ruptured aneurysm.
  • Known concomitant thoracic aortic aneurysm which requires surgical intervention.
  • Renal insufficiency defined as creatinine > 2.5 mg/dL or patient undergoing dialysis.
  • New York Heart Association (NYHA) class IV.
  • Aneurysmal, dissected, heavily calcified, or heavily thrombosed landing zone(s).
  • Severely tortuous or stenotic iliac and / or femoral arteries.
  • Patient has body habitus or other medical condition which prevents adequate delineation of the aorta.
  • Participating in another investigational device or drug study within 1 year of treatment.
  • Systemic infection which may increase the risk of endovascular graft infection.
  • Known degenerative connective tissue disease; e.g., Marfan or Ehler-Danlos Syndrome.
  • Planned concomitant surgical procedure or major surgery within 30 days of treatment date
  • Known history of drug abuse.
  • Known sensitivities or allergies to the device materials.

Eligibility last updated 6/13/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Jill Colglazier, M.D.

Cerrado para la inscripción

Contact information:

Jessica Schneider

(507) 255-7249

Schneider.Jessica1@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20201661

Mayo Clinic Footer